keyword
MENU ▼
Read by QxMD icon Read
search

neo-adjuvant chemotherapy

keyword
https://www.readbyqxmd.com/read/28806981/understanding-the-potentiality-of-accelerator-based-boron-neutron-capture-therapy-for-osteosarcoma-dosimetry-assessment-based-on-the-reported-clinical-experience
#1
Silva Bortolussi, Ian Postuma, Nicoletta Protti, Lucas Provenzano, Cinzia Ferrari, Laura Cansolino, Paolo Dionigi, Olimpio Galasso, Giorgio Gasparini, Saverio Altieri, Shin-Ichi Miyatake, Sara J González
BACKGROUND: Osteosarcoma is the most frequent primary malignant bone tumour, and its incidence is higher in children and adolescents, for whom it represents more than 10% of solid cancers. Despite the introduction of adjuvant and neo-adjuvant chemotherapy that markedly increased the success rate in the treatment, aggressive surgery is still needed and a considerable percentage of patients do not survive due to recurrences or early metastases. Boron Neutron Capture Therapy (BNCT), an experimental radiotherapy, was investigated as a treatment that could allow a less aggressive surgery by killing infiltrated tumour cells in the surrounding healthy tissues...
August 15, 2017: Radiation Oncology
https://www.readbyqxmd.com/read/28800861/ipatasertib-plus-paclitaxel-versus-placebo-plus-paclitaxel-as-first-line-therapy-for-metastatic-triple-negative-breast-cancer-lotus-a-multicentre-randomised-double-blind-placebo-controlled-phase-2-trial
#2
Sung-Bae Kim, Rebecca Dent, Seock-Ah Im, Marc Espié, Sibel Blau, Antoinette R Tan, Steven J Isakoff, Mafalda Oliveira, Cristina Saura, Matthew J Wongchenko, Amy V Kapp, Wai Y Chan, Stina M Singel, Daniel J Maslyar, José Baselga
BACKGROUND: The oral AKT inhibitor ipatasertib is being investigated in cancers with a high prevalence of PI3K/AKT pathway activation, including triple-negative breast cancer. The LOTUS trial investigated the addition of ipatasertib to paclitaxel as first-line therapy for triple-negative breast cancer. METHODS: In this randomised, placebo-controlled, double-blind, phase 2 trial, women aged 18 years or older with measurable, inoperable, locally advanced or metastatic triple-negative breast cancer previously untreated with systemic therapy were recruited from 44 hospitals in South Korea, the USA, France, Spain, Taiwan, Singapore, Italy, and Belgium...
August 8, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28764688/developing-a-patient-decision-aid-for-the-treatment-of-women-with-early-stage-breast-cancer-the-struggle-between-simplicity-and-complexity
#3
W Savelberg, T van der Weijden, L Boersma, M Smidt, C Willekens, A Moser
BACKGROUND: A patient decision aid (PtDA) can support shared decision making (SDM) in preference-sensitive care, with more than one clinically applicable treatment option. The development of a PtDA is a complex process, involving several steps, such as designing, developing and testing the draft with all the stakeholders, known as alpha testing. This is followed by testing in 'real life' situations, known as beta testing, and then finalising the definite version. Our aim was developing and alpha testing a PtDA for primary treatment of early stage breast cancer, ensuring that the tool is considered relevant, valid and feasible by patients and professionals...
August 1, 2017: BMC Medical Informatics and Decision Making
https://www.readbyqxmd.com/read/28761726/phase-i-study-of-neoadjuvant-chemotherapy-with-s-1-and-oxaliplatin-for-locally-advanced-gastric-cancer-neo-g-sox-pi
#4
Hironaga Satake, Akira Miki, Masato Kondo, Takeshi Kotake, Yoshihiro Okita, Yukimasa Hatachi, Hisateru Yasui, Yukihiro Imai, Chihiro Ichikawa, Kenta Murotani, Hiroki Hashida, Hiroyuki Kobayashi, Masahito Kotaka, Takeshi Kato, Satoshi Kaihara, Akihito Tsuji
BACKGROUND: The prognosis of locally advanced gastric cancer, such as clinical T4 disease, bulky nodal involvement, type 4 and large type 3 gastric cancer, remains unsatisfactory, even with D2 gastrectomy followed by adjuvant chemotherapy. One promising approach is neoadjuvant chemotherapy. Combination chemotherapy with S-1 and oxaliplatin (SOX) is recognised as a potentially promising regimen for gastric cancer. However, the use of neoadjuvant chemotherapy consisting of SOX for locally advanced gastric cancer has not been reported...
2017: ESMO Open
https://www.readbyqxmd.com/read/28741395/predictive-value-of-the-age-adjusted-charlston-co-morbidity-index-on-peri-operative-complications-adjuvant-chemotherapy-usage-and-survival-in-patients-undergoing-debulking-surgery-after-neo-adjuvant-chemotherapy-for-advanced-epithelial-ovarian-cancer
#5
Andrew Phillips, Kavita Singh, Rachel Pounds, Sudha Sundar, Sean Kehoe, James Nevin, Ahmed Elattar, Janos Balega
The aim of this study was to determine whether the age-adjusted Charlston co-morbidity index (ACCI) can predict post-operative complications, adjuvant chemotherapy usage and overall survival (OS) in patients with advanced epithelial ovarian cancer (AOC) treated with neoadjuvant chemotherapy (NACT). A review was performed of all cytoreductive surgeries performed between 16/8/07-3/2/14 for AOC at a UK Cancer Centre. All surgeries were stratified by ACCI into three groups: Low (0-1), Intermediate (2-3) and High (≥4)...
July 25, 2017: Journal of Obstetrics and Gynaecology: the Journal of the Institute of Obstetrics and Gynaecology
https://www.readbyqxmd.com/read/28721098/patient-selection-for-cytoreductive-surgery-and-hipec-for-the-treatment-of-peritoneal-metastases-from-colorectal-cancer
#6
REVIEW
Geert A Simkens, Koen P Rovers, Simon W Nienhuijs, Ignace H de Hingh
Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is a viable option for selected patients with peritoneal metastases (PM) from colorectal origin, resulting in long-term survival and even cure in some cases. However, adequate patient selection for this treatment is currently one of the major challenges. The aim of this review is to provide a comprehensive overview of clinically relevant factors associated with overall survival. This may help to guide clinicians through the complex interplay of patient, tumor, and treatment characteristics to adequately select patients who benefit the most from this extensive surgical treatment...
2017: Cancer Management and Research
https://www.readbyqxmd.com/read/28718942/the-shift-toward-neo-adjuvant-chemotherapy-and-interval-debulking-surgery-for-management-of-advanced-ovarian-and-related-cancers-in-a-population-based-setting-impact-on-clinical-outcomes
#7
James L Nicklin, Shaun McGrath, Lee Tripcony, Andrea Garrett, Russell Land, Amy Tang, Lewis Perrin, Naven Chetty, Nisha Jagasia, Alex J Crandon, Marcelo Nascimento, Graeme Walker, Karen Sanday, Andreas Obermair
OBJECTIVES: The aim of this study was to determine the proportion of patients with advanced ovarian and related cancers (EOC+RC), treated with neoadjuvant chemotherapy and interval debulking surgery (NACT - IDS), and to determine if there was any relationship with optimal cytoreduction rates and overall survival (OS) in a state-wide gynaecologic oncology service over time. METHODS: A retrospective review was undertaken using a population-based database of patients with stages 3 and 4 EOC+RC treated from 1982 till 2013 at the Queensland Centre for Gynaecological Cancer (QCGC)...
July 18, 2017: Australian & New Zealand Journal of Obstetrics & Gynaecology
https://www.readbyqxmd.com/read/28717754/surgical-management-of-breast-cancer-in-africa-a-continent-wide-review-of-intervention-practices-barriers-to-care-and-adjuvant-therapy
#8
REVIEW
Stephanie A Sutter, Aaron Slinker, Deo Darius Balumuka, Katrina B Mitchell
Breast cancer has emerged as a leading cancer among women in Africa, necessitating improved understanding of its management across the continent. Although previous studies have described regional trends in therapy, this review aims to summarize continent-wide management and focus specifically on surgical interventions. Current literature shows that the rates of surgery, chemotherapy, and radiation therapy vary across different countries and institutions, indicating the need for greater use of standardized cancer treatment guidelines...
April 2017: Journal of Global Oncology
https://www.readbyqxmd.com/read/28717136/association-of-plasma-and-urinary-mutant-dna-with-clinical-outcomes-in-muscle-invasive-bladder-cancer
#9
K M Patel, K E van der Vos, C G Smith, F Mouliere, D Tsui, J Morris, D Chandrananda, F Marass, D van den Broek, D E Neal, V J Gnanapragasam, T Forshew, B W van Rhijn, C E Massie, N Rosenfeld, M S van der Heijden
Muscle Invasive Bladder Cancer (MIBC) has a poor prognosis. Whilst patients can achieve a 6% improvement in overall survival with Neo-Adjuvant Chemotherapy (NAC), many do not respond. Body fluid mutant DNA (mutDNA) may allow non-invasive identification of treatment failure. We collected 248 liquid biopsy samples including plasma, cell pellet (UCP) and supernatant (USN) from spun urine, from 17 patients undergoing NAC. We assessed single nucleotide variants and copy number alterations in mutDNA using Tagged-Amplicon- and shallow Whole Genome- Sequencing...
July 17, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28711750/web-based-tailored-psycho-education-for-breast-cancer-patients-at-the-onset-of-the-survivorship-phase-a-multicenter-randomized-controlled-trial
#10
Jolien M Admiraal, Annette W G van der Velden, Jenske I Geerling, Johannes G M Burgerhof, Grietje Bouma, Annemiek M E Walenkamp, Elisabeth G E de Vries, Carolien P Schröder, Anna K L Reyners
CONTEXT: Many breast cancer patients have unmet informational and psychosocial needs after treatment completion. A psycho-educational intervention may be well-suited to support these patients. OBJECTIVES: The purpose of this multicenter randomized controlled trial was to examine the effectiveness of a web-based tailored psycho-educational program (ENCOURAGE) for breast cancer patients which aims to empower patients to take control over prevailing problems. METHODS: Female breast cancer patients from two hospitals in the Netherlands who recently completed (neo-)adjuvant chemotherapy were randomly assigned to standard care or 12-week access to the ENCOURAGE program providing fully automated information, problem-solving strategies, resources and services for reported problems...
July 12, 2017: Journal of Pain and Symptom Management
https://www.readbyqxmd.com/read/28709816/-current-knowledge-on-perioperative-treatments-of-non-small-cell-lung-carcinomas
#11
REVIEW
S Brosseau, C Naltet, M Nguenang, V Gounant, P Mordant, B Milleron, Y Castier, G Zalcman
Surgery is still the main treatment in early-stage of non-small cell lung cancer with 5-year survival of stage IA patients exceeding 80%, but 5-year survival of stage II patients rapidly decreasing with tumor size, N status, and visceral pleura invasion. The major metastatic risk in such patients has supported clinical research assessing systemic or loco-regional perioperative treatments. Modern phase 3 trials clearly validated adjuvant or neo-adjuvant platinum-based chemotherapy in resected stage I-III patients as a standard treatment of which value has been reassessed several independent meta-analyses, showing a 5% benefit in 5y-survival, and a decrease of the relative risk for death around from 12 to 25%...
July 11, 2017: Revue des Maladies Respiratoires
https://www.readbyqxmd.com/read/28707744/the-impact-of-molecular-subtype-on-breast-cancer-recurrence-in-young-women-treated-with-contemporary-adjuvant-therapy
#12
Hanan Alabdulkareem, Tiffany Pinchinat, Sarah Khan, Alyssa Landers, Paul Christos, Rache Simmons, Tracy-Ann Moo
Breast cancer is the leading cause of cancer death in women younger than 40 years. Triple-negative breast cancer (TNBC) and human epidermal growth factor receptor-2 (HER2) positive subtypes have a particularly poor prognosis in this age group. The purpose of this study was to compare rates of recurrence among breast cancer subtypes in young patients treated with modern adjuvant systemic therapy. A retrospective review of breast cancer patients managed at a major academic breast center between May 2000 and November 2014 was performed...
July 14, 2017: Breast Journal
https://www.readbyqxmd.com/read/28706905/a-nuanced-view-of-extrapleural-pneumonectomy-for-malignant-pleural-mesothelioma
#13
REVIEW
Isabelle Opitz, Walter Weder
Multimodality treatment including macroscopic complete resection (MCR) is currently the most effective therapy for patients with malignant pleural mesothelioma (MPM). However, the allocation to one of the possible combinations has to be discussed individually since various factors influence the decision making process. In the past years, relevant new information about the disease and the outcome of different treatment modalities have been generated, which allows a more individual allocation to the best treatment...
June 2017: Annals of Translational Medicine
https://www.readbyqxmd.com/read/28688723/focally-positive-margins-in-breast-conserving-surgery-predictors-residual-disease-and-local-recurrence
#14
E L Vos, J Gaal, C Verhoef, K Brouwer, C H M van Deurzen, L B Koppert
BACKGROUND: Re-excision after breast conserving surgery (BCS) for invasive breast cancer (IBC) can be omitted for focally positive margins in the Netherlands, but this guideline is not routinely followed. Focally positive and extensively positive margins have rarely been studied separately and compared to negative margins regarding clinicopathological predictors, residual disease incidence, and local recurrence. METHODS: All females with BCS for Tis-T3, without neo-adjuvant chemotherapy between 2005 and 2014 at one university hospital were included...
June 23, 2017: European Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28688674/a-network-meta-analysis-of-the-sequencing-and-types-of-systemic-therapies-with-definitive-radiotherapy-in-locally-advanced-squamous-cell-carcinoma-of-the-head-and-neck-lascchn-%C3%A2
#15
Katarzyna J Jerzak, Keemo Delos Santos, Ronak Saluja, Kelly Lien, Justin Lee, Kelvin K W Chan
OBJECTIVES: The current standard therapy for locally advanced squamous cell carcinoma of the head and neck (LASCCHN) is platinum-based chemotherapy plus concurrent radiotherapy (CRT), but several systemic therapies have been evaluated. We performed a Bayesian network meta-analysis (NMA) with random effects to enable direct and indirect comparisons of all existing treatment modalities for LASCCHN simultaneously. MATERIAL AND METHODS: A systematic review was conducted using MEDLINE, EMBASE, ASCO abstracts, ASTRO abstracts and the Cochrane Central of Registered Trials using Cochrane methodology to identify randomized controlled trials (RCTs) up to June 2016...
August 2017: Oral Oncology
https://www.readbyqxmd.com/read/28688082/circulating-myeloid-derived-suppressor-cells-increase-in-patients-undergoing-neo-adjuvant-chemotherapy-for-breast-cancer
#16
Robert Wesolowski, Megan C Duggan, Andrew Stiff, Joseph Markowitz, Prashant Trikha, Kala M Levine, Lynn Schoenfield, Mahmoud Abdel-Rasoul, Rachel Layman, Bhuvaneswari Ramaswamy, Erin R Macrae, Maryam B Lustberg, Raquel E Reinbolt, Ewa Mrozek, John C Byrd, Michael A Caligiuri, Thomas A Mace, William E Carson Iii
This study sought to evaluate whether myeloid-derived suppressor cells (MDSC) could be affected by chemotherapy and correlate with pathologic complete response (pCR) in breast cancer patients receiving neo-adjuvant chemotherapy. Peripheral blood levels of granulocytic (G-MDSC) and monocytic (M-MDSC) MDSC were measured by flow cytometry prior to cycle 1 and 2 of doxorubicin and cyclophosphamide and 1st and last administration of paclitaxel or paclitaxel/anti-HER2 therapy. Of 24 patients, 11, 6 and 7 patients were triple negative, HER2+ and hormone receptor+, respectively...
July 7, 2017: Cancer Immunology, Immunotherapy: CII
https://www.readbyqxmd.com/read/28687352/gemcitabine-enhances-the-transport-of-nanovector-albumin-bound-paclitaxel-in-gemcitabine-resistant-pancreatic-ductal-adenocarcinoma
#17
Carlotta Borsoi, Fransisca Leonard, Yeonju Lee, Mohamed Zaid, Dalia Elganainy, Jenolyn Francisca Alexander, Megumi Kai, Yan Ting Liu, Yaan Kang, Xuewu Liu, Eugene J Koay, Mauro Ferrari, Biana Godin, Kenji Yokoi
The mechanism for improved therapeutic efficacy of the combination therapy with nanoparticle albumin-bound paclitaxel (nAb-PTX) and gemcitabine (gem) for pancreatic ductal adenocarcinoma (PDAC) has been ascribed to enhanced gem transport by nAb-PTX. Here, we used an orthotopic mouse model of gem-resistant human PDAC in which increasing gem transport would not improve the efficacy, thus revealing the importance of nAb-PTX transport. We aimed to evaluate therapeutic outcomes and transport of nAb-PTX to PDAC as a result of (1) encapsulating nAb-PTX in multistage nanovectors (MSV); (2) effect of gem on caveolin-1 expression...
July 4, 2017: Cancer Letters
https://www.readbyqxmd.com/read/28687020/chemotherapy-administration-to-breast-cancer-patients-affects-extracellular-vesicles-thrombogenicity-and-function
#18
Anat Aharon, Anni Sabbah, Shahar Ben-Shaul, Hila Berkovich, David Loven, Benjamin Brenner, Gil Bar-Sela
Breast cancer (BC) is the most prevalent type of malignancy in women. Extracellular vesicles (EVs) are subcellular membrane blebs that include exosomes and microparticles. STUDY AIMS: To elucidate the effects of chemotherapy administration on BC patients' EVs characteristics and their effects on endothelial cells (EC) functions. METHODS: EVs were isolated from the blood samples of 54 BC patients treated by chemotherapy (25 neo-adjuvant, 29 adjuvant) and from 20 healthy women (control group)...
June 28, 2017: Oncotarget
https://www.readbyqxmd.com/read/28677012/persistent-impairments-3%C3%A2-years-after-neo-adjuvant-chemotherapy-for-breast-cancer-results-from-the-matox-project
#19
Hans-Jürgen Hurtz, Hans Tesch, Thomas Göhler, Ulrich Hutzschenreuter, Johanna Harde, Lisa Kruggel, Martina Jänicke, Norbert Marschner
PURPOSE: Although treatment for early breast cancer improved prognosis greatly, it can have significant long-term consequences, which must be considered during treatment decision. METHODS: 453 patients with neoadjuvant or adjuvant treatment intention were recruited into the MaTox project within the prospective, multicentre, population-based German TMK cohort study (Tumour Registry Breast Cancer) between 2008 and 2009. Patient-reported outcomes (PROs) on 26 treatment-related symptoms were assessed via a specifically designed questionnaire at 4 weeks, 6 months, 18 months and 3 years after start of systemic treatment...
July 5, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28676102/effects-of-an-interactive-mhealth-innovation-for-early-detection-of-patient-reported-symptom-distress-with-focus-on-participatory-care-protocol-for-a-study-based-on-prospective-randomised-controlled-trials-in-patients-with-prostate-and-breast-cancer
#20
Ann Langius-Eklöf, Marie-Therése Crafoord, Mats Christiansen, Maria Fjell, Kay Sundberg
BACKGROUND: Cancer patients are predominantly treated as out-patients and as they often experience difficult symptoms and side effects it is important to facilitate and improve patient-clinician communication to support symptom management and self-care. Although the number of projects within supportive cancer care evaluating mobile health is increasing, few evidence-based interventions are described in the literature and thus there is a need for good quality clinical studies with a randomised design and sufficient power to guide future implementations...
July 4, 2017: BMC Cancer
keyword
keyword
109145
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"